Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome Combined With Capecitabine, Bevacizumab and Camrelizumab in Metastatic Colorectal Cancer
NCT07395063Phase 2Not yet recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Immune Checkpoint Inhibitors, Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of irinotecan liposome injection, camrelizumab in metastatic colorectal cancer (mCRC), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
irinotecan liposome injectioncamrelizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07395063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07395063.